An Evidence-Based Rationale for Dose De-escalation of Subcutaneous Atezolizumab-Reference-Cited by-同舟云学术

An Evidence-Based Rationale for Dose De-escalation of Subcutaneous Atezolizumab

Published:2024-07-31 Issue:5 Volume:19 Page:779-787
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Kicken Mart P.^ORCID,Deenen Maarten J.,Moes Dirk J. A. R.,Hendrikx Jeroen J. M. A.,van den Borne Ben E. E. M.,Dumoulin Daphne W.,van der Wekken Anthonie J.,van den Heuvel Michiel M.,ter Heine Rob

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11523-024-01087-4.pdf

Reference33 articles.

1. Burotto M, Zvirbule Z, Mochalova A, Runglodvatana Y, Herraez-Baranda L, Liu SN, et al. IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications. Ann Oncol. 2023;34(8):693–702.

2. Tecentriq. SUMMARY OF PRODUCT CHARACTERISTIC - Tecentriq. 2023.

3. Pharma F. Roche hits FDA delay with subcutaneous version of Tecentriq amid manufacturing process changes 2023 [Available from: https://www.fiercepharma.com/pharma/roches-subcutaneous-tecentriq-hits-fda-delay-amid-manufacturing-process-changes].

4. Roche. Roche’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types 2023 [Available from: https://www.roche.com/media/releases/med-cor-2023-11-14].

5. Felip E, Burotto M, Zvirbule Z, Herraez-Baranda LA, Chanu P, Kshirsagar S, et al. Results of a dose-finding phase 1b study of subcutaneous atezolizumab in patients with locally advanced or metastatic non-small cell lung cancer. Clin Pharmacol Drug Dev. 2021;10(10):1142–55.